60 results about "1-aminoindan" patented technology

The subject invention provides methods of treating a subject afflicted with Parkinson's disease, memory disorder, depression, hyperactive syndrome, Attention Deficit Disorder, dementia, brain ischemia, stroke, head trauma injury, spinal trauma injury, neurotrauma, neurodegenerative disease, neurotoxic injury, multiple sclerosis, nerve damage, affective illness, schizophrenia or symptoms of withdrawal from an addictive substance, using the mesylate salt of R(+)-N-propargyl-1-aminoindan.

A process for isolating from a reaction mixture a salt of a mono-propargylated aminoindan, a process for isolating from a reaction mixture a crystalline diastereomeric salt of a mono-propargylated aminoindan, and a process for isolating from a reaction mixture a salt of enantiomerically pure N-propargyl-1-aminoindan or a salt of enantiomerically pure 6-(N-methyl, N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan. The corresponding products are also disclosed.

Disclosed are pharmaceutical preparations of R(+)-N-propargyl-1-aminoindan salts having enhanced content uniformity, processes for preparation of the compositions, and their uses.

The subject invention provides crystalline R(+)-N-propargyl-1-aminoindan, pharmaceutical compositions and methods of manufacture thereof.

The subject invention provides crystalline R(+)-N-propargyl-1-aminoindan, pharmaceutical compositions and methods of manufacture thereof.

Disclosed is crystalline R(+)-N-propargyl-1-aminoindan and racemic N-propargyl-1-aminoindan characterized by colorless crystals a pharmaceutical composition comprising the same, and the process for the manufacture and the validation thereof. Also disclosed is pure liquid R(+)-N-propargyl-1-aminoindan and a pharmaceutical composition comprising the same, and the process for the manufacture thereof.

The present invention relates to an improved process for the preparation of (R)-1-aminoindan (2), rasagiline (1) and pharmaceutically acceptable salts of rasagiline.

Methods for the treatment of Restless Legs Syndrome using R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.

A pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of R(+)-N-propargyl-1-aminoindan mesylate thereof, and less than 50% by weight of hexahydric sugar alcohols.

The invention relates to a method for preparing R-6-hydroxy-1-aminoindane through dynamic kinetic resolution. The method is characterized by using candida rugosa lipase as a biological resolution catalyst, D-(-)-O-acetyl mandelic acid as an acyl donor and a non-crystal nickel catalyst KT-02 as a racemization catalyst to carry out one-pot dynamic kinetic resolution reaction in an autoclave in the presence of hydrogen to convert 6-hydroxy-1-aminoindane to an R-6-hydroxy-1-aminoindane acyl compound and carrying out acid hydrolysis, alkali freeing, and the like on the acyl compound to obtain R-6-hydroxy-1-aminoindane with ee (enantiomeric excess) value more than 99%. The method has the characteristics of simplicity in operation, cheap and accessible racemization catalyst, complete utilization of the raw materials, high optical purity of the product, and the like, and has great guidance and application values in production and preparation of R-6-hydroxy-1-aminoindane.